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Abstract  
 
Aim: To update and integrate the recommendations for ankylosing spondylitis and 
the recommendations for the use of TNF-inhibitors (TNFi) in axial SpA (axSpA) into 
one set applicable to the full spectrum of patients with axSpA. 
Methods: Following the latest version of the EULAR Standardised Operating 
Procedures two systematic literature reviews first collected the evidence regarding all 
treatment options (pharmacological and non-pharmacological) which were published 
since 2009. After a discussion of the results in the steering group and presentation to 
the task force overarching principles and recommendations were formulated, and 
consensus was obtained by informal voting.  
Results: A total of 5 overarching principles and 13 recommendations were agreed on. 
The first 3 recommendations deal with personalised medicine including treatment 
target and monitoring. Recommendation 4 covers non-pharmacological 
management. Recommendation 5 describes the central role of non-steroidal anti-
inflammatory drugs (NSAIDs) as first choice drug treatment. Recommendations 6 to 
8 define the rather modest role of analgesics, and disprove glucocorticoids and 
conventional synthetic DMARDs for axSpA patents with predominant axial 
involvement. Recommendation 9 refers to biological DMARDs (bDMARDs) including 
TNF- and IL17-inhibitors (TNFi, IL17i) for patients with high disease activity despite 
the use (or intolerance/contraindication) of at least 2NSAIDs. In addition, they should 
either have an elevated CRP and/or definite inflammation on MRI and/or radiographic 
evidence of sacroiliitis. Current practice is to start with a TNFi. Switching to another 
TNFi or an IL-17i is recommended in case TNFi fails (recommendation 10). Tapering, 
but not stopping a bDMARD, can be considered in patients in sustained remission 
(recommendation 11). The final two recommendations (12,13) deal with surgery and 
spinal fractures. 
Conclusion: The 2016 ASAS-EULAR recommendations provide up-to-date guidance 
on the management of patients with axSpA. 
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Introduction 
Axial Spondyloarthritis (axSpA) is an inflammatory rheumatic disease with a diverse 
clinical presentation.[1] Chronic back pain is the leading symptom of the disease and 
often inflammatory in nature with pronounced stiffness and improvment of pain and 
stiffness with exercise. Other musculoskeletal manifestations of axSpA are arthritis, 
enthesitis and dactylitis. Extra-articular manifestations such as anterior uveitis, 
psoriasis and inflammatory bowel disease (in order of decreasing prevalence) are 
also characteristic for axSpA[2]. Historically, end-stage patients were recognised by a 
characteristic stooped posture and by the presence of syndesmophytes on 
radiographs of the spine. Later, radiographic sacroiliitis became a crucial finding in 
the diagnosis and classification of patients. The modified New York criteria for 
ankylosing spondylitis (AS) were most frequently used in studies and drug trials.[3] 
Only recently it has been properly acknowledged that radiographic sacroiliitis is a 
rather late finding in the disease course of many patients, that magnetic resonance 
imaging (MRI) may show signs of inflammation much earlier than radiographs show 
structural damage, and that patients can also be diagnosed based on a typical 
clinical pattern, even in the presence of normal imaging tests.[1,4] The term axSpA 
comprises the whole spectrum of patients with radiographic sacroiliitis (AS or 
radiographic axSpA) and without radiographic sacroiliitis (non-radiographic 
axSpA).[4] 
There is still some debate as to whether radiographic and non-radiographic axSpA 
should be considered as two different entities or as a continuous disease spectrum. 
The currently prevailing opinion is that axSpA encompasses one disease spectrum in 
which single patients with non-radiographic axSpA may develop radiographic 
changes over time.[5] However, not all patients with non-radiographic axSpA will 
ultimately develop radiographic sacroiliitis. Similarly, not all patients with radiographic 
sacroiliitis will ultimately develop syndesmophytes. In fact, radiographic sacroiliitis 
artificially divides the spectrum of axSpA in two groups, and it is unlikely that the sole 
presence of radiographic sacroiliitis is relevant for the outcome of the disease. In 
addition, recent studies and trials have cast doubt on the reliability of establishing 
radiographic abnormalities.[6-10] Taken together, there is ample argument to use 
only the term axSpA in clinical practice.[11] Especially in the context of studies it may 
be of value to add certain characteristics to the profile of patients, such as the 
presence of radiographic sacroiliitis, the presence of inflammation on MRI, the 
presence of arthritis, of extra-articular manifestations, to describe in detail the type of 
patients included.[5]  
Apart from historical reasons, drug development has played a major role in 
distinguishing patients based on the presence of radiographic sacroiliitis: TNF-
inhibitor (TNFi) therapy was historically approved for patients with AS, and 
companies sought the additional regulatory approval for patients without radiographic 
sacroiliitis.[12-17] The newest draft guidance document of the European Medicines 
Agency now proposes to study patients with axSpA as one entity, which testifies of 
the progress in the field of axSpA.[18] 
Historically, the Assessment of SpondyloArthritis international Society (ASAS) has 
drafted two sets of treatment recommendations, dating back to the time when TNFi 
were the only class of biological Disease Modifying Anti Rheumatic Drugs 
(bDMARDs) and the concept of axSpA was not yet well established. However, it 
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should be noted that there is no formal proof that TNF I are in fact disease modifying 
in axSpA. The first set included the ASAS recommendations for the use of TNFi 
therapy in patients with AS published first in 2003 and updated in 2006 and 2010. 
[19-21] In contrast to existing recommendations for the use of bDMARDs in 
rheumatoid arthritis (RA) and psoriatic arthritis (PsA), the ASAS recommendations on 
the use of TNFi in AS include specific definitions for the level of disease activity 
required before a TNFi can be installed.[22,23] The second set of recommendations 
that ASAS has drafted in collaboration with the European League Against 
Rheumatism (EULAR) included recommendations for the management of AS 
published first in 2006 and updated in 2010.[24,25] In line with a better delineation 
and acceptance of axSpA, in follow up of the advent and approval of another class of 
bDMARDs (IL17-pathway inhibitors, IL17i), and after the publication of studies with 
patients covering the entire spectrum of axSpA, it was felt timely to integrate all 
different aspects of management into one set of recommendations and update the 
recommendations accordingly.[26-28] However, we have to acknowledge that the 
term bDMARDs is not completely correct as the disease-modifying aspect has not 
yet been proven in axial SpA. 
This document presents the 2016 ASAS/EULAR management recommendations for 
the management of patients with axSpA and details the process of their 
development. 
 
Methods 
This was a combined project endorsed and financed by both ASAS and EULAR. One 
aim of this update was to aggregate the existing ASAS-EULAR management 
recommendations of AS and the ASAS recommendations for the management of 
axSpA with TNFi into one set of recommendations. The objective of this aggregated 
set of recommendations is to give guidance on the non-pharmacological and 
pharmacological management of patients with axSpA.  
The 2014 updated EULAR standardised operating procedures have been 
applied.[29] These prescribe that the process set out in AGREE II should be followed 
in order to design the recommendations and to write the manuscript.[29,30] The 
convenors formed first a task force with a steering committee. The steering 
committee included the convenor (DvdH), co-convenor (JB), methodologist (SR), two 
fellows who performed the SLRs (AS, AR), and three expert-rheumatologists (RL, 
XB, FvdB). The steering committee defined the research questions for the SLRs and 
prepared the one-day meeting of the task force. This task force included in addition 
to the steering committee 18 rheumatologists (two of them with axSpA), including 3 
members of EMEUNET (AM, PM, VNC), one health professional (HD) and two 
patient partners (MJ, DW). The members of the task force represent 14 countries in 
Europe, North- and South America. All members of the task force disclosed their 
potential conflicts of interest before the start of the process. 
Two fellows under the guidance of the methodologist performed two SLRs: one on 
non-pharmacological and non-biological pharmacological treatment (AR) and one on 
biological and targeted synthetic disease modifying antirheumatic drugs (DMARDs) 
(AS). These SLRs focused on the studies published after the locking date of the 
SLRs for the previous update, i.e. 2009. The two SLRs are published in detail 
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separately.[31,32] These SLRs and the current recommendations manuscript form 
an integral and inseparable part and should be read as such. Both SLRs addressed 
efficacy and safety, but because the literature on safety of specific drugs in axSpA 
was, as shown by the SLRs, somewhat limited, more extensive evidence collected 
on these drugs in SLRs for Rheumatoid Arthritis (RA) were also taken into 
account.[31-33] The evidence collected was presented in Summary of Findings (SoF) 
tables and included judgements about Risk of Bias, which was determined for every 
study.[34,35] SoF tables were presented to the Steering Committee in writing and by 
presentation, and served as the basis for the discussion in the full task force. When 
discussing the update of the recommendations, the evidence collected in the 
previous SLRs was also taken into consideration.[36-38]  
In addition, the fellows performed an SLR on the research question whether 
Ankylosing Spondylitis Disease Activity Score (ASDAS) or Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) should be applied to best define disease 
activity for the start and continuation of bDMARDs (see Online Supplementary Text 
1). 
Based on the data obtained from the systematic literature search (SLR), the steering 
committee prepared wording for the update of the overarching principles and 
recommendations. The overarching principles and recommendations from the 2010 
update were used as a basis and were updated if considered necessary. It was 
decided that recommendations could only be updated if there was new evidence 
available that justified such an update according to the task force.  
The task force met for a one-day meeting. First, the results of the SLRs were 
presented to the participants. Thereafter, the updating process of the overarching 
principles and recommendations was done by discussion in the group. For every 
overarching principle and recommendation proposed formulations were presented, 
discussed and voted upon (informal voting). If at least 75% approved the new 
wording, this was accepted. If not, discussion was resumed and changes to the 
wording were proposed. In the second voting round a 67% majority was required to 
accept the recommendation. If this was not reached, a further round of discussion 
followed and completed with a vote in which a simple majority was deemed sufficient. 
After the meeting, the levels of evidence (LoE) and grades of recommendation (GoR) 
derived from the SLRs following the standards of the Oxford Centre for Evidence 
Based Medicine were added to each of the recommendations.[39] In summary, level 
1A refers to evidence stemming from a meta-analysis of RCTs, 1B corresponds to at 
least one RCT, 2A means that there was at least one controlled study without 
randomisation, 2B at least one type of quasi-experimental study, 3 corresponds to 
descriptive studies, such as comparative studies, correlation studies or case-control 
studies, and 4 means from expert committee reports or opinions and/or clinical 
experience of respected authorities. The grades of recommendation are A, which 
means consistent level 1 studies, B indicating consistent level 2 or 3 studies or 
extrapolations from level 1 studies, grade C meaning level 4 studies or extrapolations 
from level 2 or 3 studies and grade D reflecting level 5 evidence or troublingly 
inconsistent or inconclusive studies of any level. Finally, the overarching principles 
and recommendations were sent to the task force members and they were asked to 
add the level of agreement anonymously to each of the statements. This was done 
by numerical rating scale (NRS, 0-10) with the anchors ‘do not agree at all’ at 0 and 
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‘fully agree’ at 10. The average, standard deviation and range of the level of 
agreement per recommendation, as well as the percentage of participants with a 
score of at least 8, are presented. 
The exact wording of the recommendations was considered final after the end of the 
one-day task force meeting. The final manuscript was drafted after the meeting, 
reviewed, revised and approved by all task force members, followed by final review 
and ratification by the EULAR Executive Committee and ASAS Executive Committee 
before submission to the journal.  
 
Results 
It was decided to use the same terminology for DMARDs as proposed recently: 
conventional synthetic (cs) DMARDs for drugs such as sulfasalazine and 
methotrexate; targeted synthetic (ts) DMARDs for drugs such as tofacitinib; and 
biological (b) DMARDs for drugs such as TNFi and IL-17i. bDMARDs can further be 
subdivided into bio-originator (bo) and biosimilar (bs) DMARDs. Only DMARDs that 
were approved in at least one country with an indication for axSpA were considered 
in the recommendations process.[40] However, all DMARDs were looked at in the 
SLRs.  
The target-users of these recommendations are: “All health care professionals taking 
care of patients with axSpA”. While this definition will mainly include practicing 
rheumatologists, it may also include medical specialists of a different discipline, 
general practitioners, physical therapists and other health professionals, as well as 
medical students. These recommendations further aim at patients to be educated for 
informed / shared decision-making. The final target group is pharmaceutical industry 
in its broadest sense, national drug-agencies and policy makers, as well as health 
insurance companies.   
The recommendations describe all aspects of the management of patients with a 
diagnosis of axSpA. Many of these patients will also fulfil the ASAS classification 
criteria for axSpA.[41] The focus of these recommendations is on the 
musculoskeletal signs and symptoms of the disease. But when appropriate and 
relevant, extra-articular manifestations such as psoriasis, uveitis and inflammatory 
bowel disease, as well as comorbidities including osteoporosis and cardiovascular 
diseases, will also be discussed. However, the actual management of these extra-
articular manifestations and comorbid conditions are beyond the scope of these 
management recommendations. For the optimal management of these diseases, 
specific EULAR recommendations and respective medical specialists should be 
consulted.[42-44]  
As the concept and term of axSpA is relatively new, the older studies in the literature 
are based only on patients with AS. This applies mainly to non-pharmacological 
treatments and to drugs that are already on the market for a long time, such as non-
steroidal anti-inflammatory drugs (NSAIDs). However, the two SLRs revealed many 
trials that have included patients with the whole spectrum of axSpA, mainly trials with 
TNFi but also trials with NSAIDs and DMARDs. The task force agreed explicitly that 
these recommendations apply to all patients with axSpA.  
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Overarching principles 
As in the 2010 update, the recommendations start with overarching principles, which 
are considered so generic and implicit in nature that they serve as a basis for the 
state-of-the-art management of patients with axSpA. As such, they reflect the state of 
practice rather than the state of science. There are in total 5 overarching principles; 4 
are identical to the previous version and one new overarching principle was 
formulated. Only the order of the previous overarching principles 3 and 4 was 
switched. We present the LoA of each overarching principle in table 1. 
  
1. Axial Spondyloarthritis (axSpA) is a potentially severe disease with diverse 
manifestations, usually requiring multidisciplinary management coordinated by the 
rheumatologist 
This overarching principle is important, not only because it stresses that 
musculoskeletal manifestations of the disease may importantly interfere with patients’ 
daily living, but also because it points to the fact that patients with axSpA frequently 
experience extra-articular manifestations: approximately 40% of the patients 
experience at least one extra-articular manifestation during the course of the 
disease.[2,45]. Some of these extra-articular manifestations require the immediate 
consultation of other experts, pointing to the presence of multidisciplinary networks 
for the best care of patients with axSpA.  Some of the available (biological) drugs are 
efficacious for both musculoskeletal and the extra-articular manifestations, while 
others have effects limited to the musculoskeletal symptoms. These factors should 
be taken into account when choosing a drug. Since the treating rheumatologist 
should have extensive knowledge of the entire disease spectrum, it is crucial that the 
rheumatologist is the coordinator in a multidisciplinary network of care for patients 
with axSpA. In this network, other medical specialists and care professionals do of 
course also have their place. 
2. The primary goal of treating the patient with axSpA is to maximise long term health 
related quality of life through control of symptoms and inflammation, prevention of 
progressive structural damage, preservation/normalisation of function and social 
participation. 
Management should aim at the best possible health-related quality of life. Many 
studies have clearly shown that patients with axSpA have a reduced quality of life in 
comparison to the non-diseased population[46,47]. Problems experienced by 
patients with axSpA can be summarised according to the International Classification 
of Functioning, Disability and Health and can be assessed using the ASAS Health 
Index, which is based on the ICF.[48-50] As axSpA is an inflammatory disease, 
suppression of inflammation by drugs has a prominent place, in order to relieve 
symptoms, preserve physical function and maintain quality of life. And indeed, data 
have accrued that suggest a direct relation between clinical disease activity and 
syndesmophyte formation and between disease activity and function.[51-53] 
Moreover, patients who have inactive disease have a better health-related quality of 
life.[54] 
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3. The optimal management of patients with axSpA requires a combination of non-
pharmacological and pharmacological treatment modalities. 
This overarching principle is identical to number 4 in the 2010 set of 
recommendations. 
In comparison to other chronic inflammatory rheumatic diseases such as RA and 
PsA, non-pharmacological management has a relatively important place in the 
management of patients with axSpA. While this will be highlighted in the separate 
recommendations, the task force wanted to draw attention to the importance of non-
pharmacological treatment by formulating it as an overarching principle. 
4. Treatment of axSpA should aim at the best care and must be based on a shared 
decision between the patient and the rheumatologist. 
This is an unchanged principle but is now listed as the fourth overarching principle. 
‘Best care’ is an important concept and closely relates to overarching principle 2: ‘to 
maximise health related quality of life’. But ‘best care’ here refers to the ‘best possible 
care’ for individual patients, and still prevails when costs of treatment are taken into 
account, as indicated in the following fifth overarching principle.  
‘Shared decision making’ is the second important concept in this overarching 
principle and refers to the formal and informal relationship between patient and 
rheumatologist, that partner during all phases of their encounters, in order to 
collectively decide upon the best possible management, given all factors that may be 
relevant for such a decision. ‘Shared decision’ does not only refer to the choice of a 
particular drug but pertains to all phases of the process: defining a treatment-goal 
(target), investigating potential barriers to achieve that target, choosing the best 
strategy to achieve the target (given the potential barriers), considering alternative 
strategies if the target is not reached or the treatment is not tolerated, considering 
tapering strategies if a target is ‘sustained’, etcetera. Shared decision making 
requires sufficient education about the disease, appropriate information (that means: 
comprehensible risk communication) about risks and benefits of separate treatment 
options and the design of a feasible management plan, as well as strategies to 
monitor treatment success. In this process of shared decision making, 
rheumatologists and patients have different roles and responsibilities that ideally 
should merge into one management plan with full commitment from patient and care-
giver, so that the likelihood of treatment success and good compliance is highest. 
 
5. AxSpA incurs high individual, medical and societal costs, all of which should be 
considered in its management by the treating rheumatologist. 
This is a new overarching principle which has been taken from the EULAR 
recommendations on RA and PsA.[22,23] This overarching principle first points to the 
fact that there are high costs associated with the disease itself and with its treatment. 
This relates to the patient (individual costs) and can be seen as monetary costs, but 
also as burden of the disease. When assessing the financial burden for society, the 
direct medical costs as well as indirect costs due to work productivity loss should be 
taken into account. And when evaluating the cost-effectiveness of (potentially 
expensive) treatments, all these aspects should be considered.[55]  
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AxSpA is a disease for which the treatment options rapidly increase. Some of them 
are very cheap; others are very expensive. When a choice between treatments has 
to be made in clinical practice, costs in its broadest sense are relevant factors. This 
should only be done taking ‘best care’ as worded in overarching principle number 4 
into account. Consequently, only if the outcome for the patient is expected to be 
similar under either treatment, healthcare costs can drive the choice This is an 
important principle in light of the fact that in many (Western) countries the pressure to 
reduce cost of healthcare through cuts on drug expenditure has increased 
significantly. Several task force members, including patients, expressed major 
concerns regarding this overarching principle, because of the historical -but currently 
untenable- premise that physicians should not be influenced by drug costs when 
making decisions, and because of the fear to be hindered in choosing the treatment 
that may provide ‘best care’. Nevertheless, the vast majority (see LoA) of task force 
members were supportive of this principle after highlighting the fact that the principle 
of ‘best care’ (and that of shared decision making) should always prevail. An 
appropriate example of the above mentioned discussion could be the choice between 
a cheaper bsDMARD and a (likely) more expensive boDMARD. In this scenario 
similar (efficacy and safety) outcomes can be reasonably expected, and the price of 
the drug may become a prevailing argument, provided that the patient is fully 
informed and agrees with this choice under the premise of ‘shared decision making’. 
Moreover, drug costs as well as costs of treatment can vary tremendously not only 
across countries, but between different regions within the same country (e.g. due to 
price negotiations among payers). It is therefore strongly recommended to consider 
costs of treatment in the context of the local situation.  
The task force is keen to point out that although no dedicated SLR on cost-
effectiveness was performed, costs have been taken into account at all times during 
the development of these recommendations. 
 
Recommendations 
A total of 13 recommendations have been formulated (Table 1). Two of these (#3, 
#11) are new from previous publications, one recommendation was split into two (old 
#9 into new #9, #10) and one recommendation has been deleted (old #4). The 
deleted recommendation dealt with the management of extra-articular manifestations 
and comorbidities. The task force decided that these aspects were already 
sufficiently covered by the overarching principles and by other recommendations. 
Comparing to the 2010 recommendations, the new recommendations are far better 
formulated as recommendations. In hindsight, the 2010 recommendations 
represented in realilty ‘statements’, which were based on findings of evidence in the 
literature and/or on expert opinion. The current recommendations are far more 
specific and prescribe what should be done in particular clinically relevant situations. 
These improvements reflect a general tendency of moving insight into 
recommendation development over the last decade. Moreover, LoE and GoR are 
now clearly added to each recommendation (Table 1). 
Recommendation 1 
The treatment of patients with axSpA should be individualised according to the 
current signs and symptoms of the disease (axial, peripheral, extra-articular 
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manifestations) and the patient characteristics including comorbidities and 
psychosocial factors. 
The content of the first recommendation is largely unchanged, and indicates the 
importance of personalized management in a disease with a very heterogeneous 
phenotype. All the factors mentioned in the body of the text may play a role in making 
decisions about aspects of management. It also points to the fact that group-level 
results of trials in patients with axSpA often suggest a certain level of homogeneity, 
but that individual patients with axSpA in clinical practice may deviate from this 
supposedly homogeneous pattern. Rheumatologists should take this principle of 
generalizability into consideration when treating patients with axSpA.    
Recommendation 2 
Disease monitoring of patients with axSpA should include patient reported outcomes, 
clinical findings, laboratory tests and imaging, all with the appropriate instruments 
and relevant to the clinical presentation. The frequency of monitoring should be 
decided on an individual basis depending on symptoms, severity, and treatment. 
Due to the heterogeneous presentation of the disease, monitoring should include a 
broad variety of assessments. In principle, the ASAS core set for monitoring in 
clinical practice is still guiding.[56] This includes questionnaires for levels of pain, 
disease activity (BASDAI), and physical function (Bath Ankylosing Spondylitis 
Functional Index, BASFI), swollen joint counts, spinal mobility and assessment of 
extra-articular manifestations if appropriate.[56] Acute phase reactants now play a 
more prominent role in monitoring patients with axSpA than before. The ASDAS is a 
relatively new disease activity score, which combines patient reported outcomes and 
C-reactive protein (CRP) (or erythrocyte sedimentation rate - ESR) into one 
index.[57] It has been proven that there is a longitudinal relationship between ASDAS 
and subsequent syndesmophyte formation, while such a relationship between 
BASDAI (even if combined with CRP in the model) and syndesmophytes was far 
weaker.[51] Although not (yet) included in the ASAS core set (which was defined 
before the development of the ASDAS), ASDAS seems a relevant measure to 
assess disease activity. 
MRI is an imaging modality that can provide information on inflammation. Both MRI 
of the sacro-iliac (SI) joints and of the spine can be used for this purpose. In early 
disease MRI of the SI joints may be most relevant, while in later stages especially the 
MRI of the spine may be informative.[28,58]  However, the correlation between 
clinical disease activity measures and MRI inflammation is modest at best.[59-62] To 
date, the role (if any) of MRI in monitoring the disease remains unclear. Apart from 
the fact that the meaning of MRI inflammation in patients who have clinically inactive 
disease (they are free of symptoms) is unclear and that it is unknown if residual MRI 
inflammation can and should be treated, it is simply not feasible in most settings and 
far too expensive to repeat MRIs frequently. This explains why MRI is currently not 
recommended for monitoring. However, MRI can be used to define the level of 
present inflammation, and may add arguments to the global opinion to start or 
continue a particular treatment in a particular patient.  
Radiographs of the SI joints are useless to monitor the disease course, but may be 
necessary to define if a patient is fulfilling criteria for a bDMARD start (see later). In 
contrast, radiographs of the spine provide important information about the presence 
of syndesmophytes, and about the prognosis of an individual patient, since 
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evidences show that this is a risk factor for developing more syndesmophytes.[51,53] 
However, monitoring the disease by consecutive spinal radiographs is of limited 
value, because of the very slow rate of progression in the majority of patients. If 
applied, it should not be performed more frequently than once every 2 years.    
Recommendation 3 
Treatment should be guided according to a predefined treatment target. 
This is an important aspect of the treat-to-target concept and is newly added to the 
recommendations. For the first time in the history of SpA-research, evidence has 
been accrued to suggest the value of ‘targetting disease activity’ because disease 
activity leads to new syndesmophytes in patients with axial SpA.[51,53] As described 
in the overarching principles, a target should be a shared decision between patient 
and rheumatologist, taking all relevant situational factors into consideration. 
Treatment, once started, should be monitored in order to investigate if the target is 
reached. While amply discussed, the task force did not want to establish a preferred 
target (as has been done in RA and PsA). In principle, inactive disease is the ultimate 
goal, but depending on the phase of the disease and the treatments already used 
previously, it was felt that the required treatment for reaching this target (including its 
inherent risks) could imply an unrealistic goal. So after discussion it was decided that 
it is important to recommend that a target should be defined and documented, but 
refrain from mentioning the content of such target. 
Recommendation 4  
Patients should be educated about axSpA and encouraged to exercise on a regular 
basis and stop smoking; physical therapy should be considered. 
Education is an important aspect of management, it is essential for patients to make 
informed shared decisions and has been proven to be efficacious[63-65]. In axial 
SpA, it is known that home exercises are efficacious and these are therefore 
recommended to patients.[66] However, physical therapy is proven to be more 
efficacious than home exercises.[66] Physiotherapy is certainly more expensive and 
less feasible than home exercises but may be required in some patients. 
Consequently, it is recommended that rheumatologists always consider if physical 
therapy could be beneficial for a particular patient. While quitting smoking likely has 
favourable health effects for every individual, it is of particular interest for axSpA 
patients, since there is an established association between smoking and disease 
activity, inflammation on MRI, and syndesmophyte formation.[67-69] In spite of these 
positive associations, to date there are no data showing a beneficial effect of 
smoking cessation on signs and symptoms of patients with axSpA.  
Recommendation 5 
Patients suffering from pain and stiffness should use an NSAID as first line drug 
treatment up to the maximum dose, taking risks and benefits into account. For 
patients who respond well to NSAIDs continuous use is preferred if symptomatic 
otherwise. 
The most important aspect of this 2010-recommendation on the use of NSAIDs as 
first line drug was maintained in the text of this recommendation. All task force 
members were still convinced of the virtues of NSAIDs administered in a full anti-
inflammatory dosage. This can for example be based on the ASAS20 response of 
above 70%, an ASAS40 response in more than 50% of the patients starting with an 
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NSAID in early disease or 35% of patients in ASAS partial remission.[70] Important 
consideration however needs to be given to the potential side effects of NSAIDs, 
especially when administered chronically. NSAIDs should therefore only be 
prescribed if patients are symptomatic. If so, treatment should be advised to the 
maximum tolerated dose, continuously weighing the risks against the benefits. 
Moreover, while there is much discussion on the long-term safety of NSAIDs 
especially in relatively young patients data from two studies have suggested that lack 
of exposure to NSAIDs is associated with an increase in mortality.[71,72] This argues 
against a major or important safety problem associated with the use of NSAIDs. 
Given the risks of long-term NSAID use, the question about which patients require 
continuous NSAID treatment is valid: trial data have suggested that the continuous 
use of NSAIDs in patients with an elevated CRP results in reduced progression of 
structural damage in the spine in comparison to on demand use only.[73,74] Similar 
results were found in a in a cohort study comparing high and low dose NSAID 
use.[75] However, a recent randomised trial did not confirm this effect, casting doubts 
on the potential structural effects of NSAIDs.[76] It was suggested during the task 
force discussions that the protective effects of NSAIDs may be specific for certain 
NSAIDs.[76] In the absence of equivocal evidence, it was finally decided to base a 
decision of continuous use of NSAIDs to the symptoms of the patient rather than on a 
possible protective effect regarding structural progression: if symptoms recur after 
stopping or dose reduction of an NSAID, continuous use should be advised. This was 
accepted by a two third majority in the second round of voting. Whether continuous 
NSAID use may be beneficial in patients with risk factors for syndesmophyte 
progression (presence of syndesmophytes, elevated CRP, longstanding disease, 
spinal inflammation on MRI) remains a topic on the research 
agenda.[51,53,67,74,75,77-80] 
Recommendation 6 
Analgesics, such as paracetamol and opioid-(like) drugs, might be considered for 
residual pain after previously recommended treatments have failed, are 
contraindicated, and/or poorly tolerated. 
This recommendation remained unchanged. It is formulated as a rather weak 
recommendation since formal evidence that analgesics are efficacious in axSpA is 
lacking (not tested). Nevertheless, common sense justifies a statement that 
analgesics may relieve painful conditions, but only if positively recommended 
treatments for axSpA, including bDMARDs when indicated, have failed. 
Recommendation 7 
Glucocorticoid injections directed to the local site of musculoskeletal inflammation 
may be considered. Patients with axial disease should not receive long-term 
treatment with systemic glucocorticoids.  
This recommendation combines, as in the previous version, two means of 
glucocorticoid use: local and systemic. The formulation about the use of local 
injections is unchanged and indicates that the task force is still of the opinion that 
injections with glucocorticoids may be an option to treat arthritis and enthesitis, 
although direct evidence is lacking. The formulation about the use of systemic 
glucocorticoids has changed slightly. While systemic glucocorticoids were not 
specifically discouraged entirely in previous recommendations, positive data were 
also lacking. New data now have suggested that short-term high dose of 
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glucocorticoids (50mg/day) may have a very modest effect on signs and symptoms in 
patients with axial disease.[81] However, the task force still had the conviction that 
patients with axial disease should not be treated long-term with systemic 
glucocorticoids irrespective of the dose. 
 
Recommendation 8 
Patients with purely axial disease should normally not be treated with csDMARDs; 
Sulfasalazine may be considered in patients with peripheral arthritis.  
Again this recommendation consists of two parts: The first part refers to patients with 
purely axial disease and the second part to patients with peripheral arthritis. The 
latter remained identical: sulfasalazine as a treatment option in patients with 
peripheral arthritis. The statement pertaining to patients with axial disease has been 
reworded into a real recommendation, while the previous version was rather a 
statement on the lack of efficacy of csDMARDs in patients with axial SpA. There 
were no new studies on csDMARDs in axSpA. Already in the SLR informing the 
previous version of the recommendations, and on the basis of older studies, it had 
been shown that csDMARDs were not efficacious in axSpA. 
The word ‘normally’ in the text of the recommendation created a lot of argument. 
Only in the third round of voting, 65% of the participants voted in favour of adding the 
word ‘normally’. In principle, the task force was of the opinion that patients with purely 
axial disease should not be treated with csDMARDs. While there is evidence that 
sulfasalazine, methotrexate and leflunomide are not efficacious for axial symptoms, 
there may be exceptional situations in which there is no other pharmacological 
treatment option left for a particular patient for reasons of toxicity, contraindications or 
costs.[82-84] In such exceptional (‘not normal’) situations, a shared decision could be 
to try a csDMARD for a limited period of time. This policy violates the (ethical) 
principle of ‘best care’, knowing the low likelihood of treatment success, but not the 
principle of ‘shared decision making’ since the patient should be fully informed about 
the low likelihood of treatment success and the likelihood of side effects, before the 
decision is made. This reasoning convinced the majority of the task force to accept 
the wording of the recommendation in such a manner that the use of csDMARDs in 
patients with purely axial disease can only exceptionally be defended.  
Recommendation 9 
bDMARDs should be considered in patients with persistently high disease activity 
despite conventional treatments (box 1); current practice is to start with TNFi therapy.  
The previous recommendation 9 only included TNFi therapy, because no other class 
of bDMARDs was available. Moreover, the details about the use of TNFi therapy was 
discussed in the separate ASAS recommendations. Now both are integrated in the 
current recommendations. The first part of the recommendation remained essentially 
unchanged: bDMARDs (in general and not limited anymore to TNFi therapy) should 
be considered in patients with persistently high disease activity despite conventional 
treatments. These conventional treatments obviously include non-pharmacological 
management as well as NSAIDs. And in patients with (mainly) peripheral symptoms 
‘conventional management’ may also include a local glucocorticoid injection (if 
considered appropriate) and normally a treatment with sulfasalazine (in case of 
peripheral arthritis). This recommendation emphasises that a treatment ‘should be 
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considered’ and the outcome of this process of consideration is dependent on an 
evaluation of the risks and benefits to be expected. As always, shared decision 
making is key. 
Box 1 is summarizing the different requirements before a bDMARD could be started. 
The first step is the diagnosis of axSpA by a rheumatologist. Only formally fulfilling 
classification criteria (such as the ASAS axSpA criteria) does not suffice. A 
knowledgeable rheumatologist should make a diagnosis based on the full evaluation 
of all clinical, laboratory and imaging information, and should also exclude other 
potentially more likely diagnoses. While the large majority of these patients will also 
fulfil the ASAS axSpA criteria, the opposite is not necessarily true: solely checking 
and ticking boxes in order to test fulfilment of separate elements is inappropriate and 
obsolete.  
The next step is to judge if a patient fulfils ‘labelling criteria’: elevated CRP, the 
presence of inflammation on MRI of the SI joints and/or spine, or the presence of 
radiographic sacroiliitis (defined as according the modified New York grading: at least 
grade 2 bilaterally or at least grade 3 unilaterally). The clarification of the content and 
order of this step is as follows: 
TNFi therapy is approved in many countries for patients with radiographic axSpA 
(AS) without further limitations, and in patients with non-radiographic axSpA only if 
there is an elevated CRP and/or inflammation on MRI. This means that if a patient 
with axSpA has radiographic sacroiliitis or when this patient has either an elevated 
CRP or inflammation on MRI, the patient formally complies with the requirements for 
bDMARD therapy mentioned in the label of the respective drugs. While not brought 
up as a limitative factor, the task force was of the opinion that many studies have 
now suggested that also patients with radiographic axSpA that have an increased 
CRP have the highest likelihood of treatment success.[85,86] In addition, recent 
observational studies, as well as re-evaluations of clinical trials, have cast doubts on 
the reliability of the finding of radiographic sacroiliitis by (untrained) single 
evaluators.[6,7] Elaborating on this principle, one may argue that –albeit formally 
justifiable- a sole finding of radiographic sacroiliitis in a patient without further 
indication of objective disease activity may be too meagre to justify proper bDMARD 
treatment in the spirit of ‘best possible care’ as defined in overarching principle 
number 4. Therefore, the task force decided to start with ‘elevated CRP’ as being the 
strongest predictor of a good response to TNFi therapy, both in patients with 
radiographic axSpA and non-radiographic axSpA.[15,87] In addition, inflammation on 
MRI appeared to be second-best predictor of response to TNFi therapy, again 
irrespective of the presence of radiographic sacroiliitis.[13,15,17] The task force 
hopes that rheumatologists will take CRP and (when available) MRI into 
consideration when deciding about the appropriateness of starting a bDMARD, 
irrespective of whether radiographic sacroiliitis is present or not.[13,15,17,87] 
Radiographic sacroiliitis is not a predictor of response: a study stratified on 
radiographic sacroiliitis has shown that patients with radiographic and non-
radiographic sacroiliitis have similar response rates.[28] But there is one proviso 
here: while this box pertains to treatment with bDMARDs, currently the use of IL17i 
therapy and of infliximab in patients with non-radiographic axSpA is not approved by 
the agencies and therefore for IL17i therapy and infliximab radiographic sacroiliitis is 
mandatory.  
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Step 3 refers to the failure of standard treatment as explained above. A treatment 
with sulfasalazine should be evaluated after 3 months of treatment reaching a dose 
of 3g per day if tolerated. This is different in comparison to the 2010 ASAS 
recommendations, as in those recommendations MTX was also advocated as a 
possible treatment for patients with peripheral symptoms. As there are no data 
proving the efficacy of MTX and there are with regard to sulfasalazine, this was 
changed back to sulfasalazine in accordance with earlier recommendations.[20,21] 
Step 4 is to define the level of disease activity. Historically, active disease has been 
defined by a BASDAI level of at least 4. But ASDAS is a better index than BASDAI 
(see below), and active disease can also be defined by ASDAS of at least 2.1[88]. 
ASDAS is placed first, as it is the preferred measure. This decision was based on 
data from the SLR of the fellows and on expert opinion (Online Supplementary Text 
1). The BASDAI is a fully patient reported outcome while the ASDAS is a 
combination of patient reported outcomes and CRP. BASDAI and physicians’ opinion 
on disease activity only correlate weakly, while ASDAS correlates far better with both 
patients’ and physicians’ level of disease activity.[57,89] Another argument is that 
increased ASDAS may lead to syndesmophyte formation, while this has not been 
proven for BASDAI alone (BASDAI works only if combined with CRP).[51] Moreover, 
a high BASDAI appeared to be a predictor for stopping TNFi therapy, while a high 
ASDAS was a predictor for continuation of TNFis, which can be seen as a surrogate 
outcome for efficacy.[85] Frequently, there is concordance between a BASDAI 4 
and ASDAS 2.1, but in discordant cases an elevated ASDAS was more predictive of 
a good response than an elevated BASDAI.[90,91] Finally, the ASDAS cut-offs for 
disease activity states and response criteria were based on a thorough validation 
process, while the BASDAI cut-offs were arbitrarily chosen.[88] 
In addition to the level of high disease activity, the rheumatologist should be 
convinced that in a particular patient there is a favourable benefit/risk profile before a 
treatment with a bDMARD is started. In order to construct this profile intuitively, the 
rheumatologist can take ‘positive factors’ such as inflammation on MRI, into 
consideration, but should also weigh potential contraindications such as risk for side 
effects, or compliance. Ultimately, only a shared decision between patient and 
rheumatologist will result in the start of a bDMARD. 
The second part of recommendation 9 refers to ‘current practice’ in which it is normal 
to start with TNFi therapy. TNFis registered for the indication of axSpA are (in 
alphabetical order) adalimumab, certolizumab pegol, etanercept, golimumab and 
infliximab. The wording for this recommendation was borrowed from previous EULAR 
recommendations for RA at the time that TNFi were already on the market for a long 
time; there was extensive experience with the use of TNFi; TNFi were also used in 
clinical practice in a wide variety of patients; registry data suggested positive long 
term safety.[22] This is exactly how the situation is in axSpA in 2016. For the first 
time there is a different class of bDMARDs on the market with a different mode of 
action: an IL17-pathway inhibition. Currently, only secukinumab is approved, but 
several other agents are far in their development. To date, only trial data on IL17i in 
radiographic axSpA are available and data in patients with non-radiographic axSpA 
are still lacking. So it is obvious that the body of experience with TNFi in axSpA on 
efficacy, safety and variety of indications greatly outweighs that with IL17-pathway 
inhibition, both in terms of volume and time of follow up. This is why the task force 
has decided to recommend TNFi as the first bDMARD, use the wording ‘current 
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practice’ to justify that choice, and implicitly give endorsement to this practice. 
Moreover, the use of IL17i therapy should be avoided in patients with active IBD, as 
secukinumab in comparison to placebo was not efficacious in Crohn’s disease and 
resulted in more adverse events.[92] Secukinumab has proven efficacy for the 
treatment of psoriasis.[93] Apart from IL17i therapy there is no other non-TNFi 
bDMARD on the market. Various IL-6is have been tried in well-designed trials but 
were proven not efficacious.  
Several TNFi have been approved for axSpA. All, except infliximab, have indications 
for both radiographic and non-radiographic axSpA. Their efficacy with regards to 
musculoskeletal signs and symptoms seems very comparable, although no head-to-
head comparisons are available. However, there seems to be a difference in efficacy 
with regards to extra-articular manifestations. Monoclonal antibodies (infliximab, 
adalimumab, certolizumab, golimumab) are efficacious in the treatment of IBD and in 
preventing the recurrence of uveitis (no data on golimumab) and, whereas etanercept 
has shown contradictory results for uveitis and no efficacy in IBD.[94-103] Etanercept 
seems to be less efficacious for psoriatic skin involvement than other TNFi, although 
no head-to-head comparisons are available.[23]  
In this entire document, we refer to both boDMARDs as well as bsDMARDs when we 
mention TNFi therapy. The price of a bDMARD should be taken into account when 
choosing a particular drug. The choice is very much dependent on local situations, 
and general recommendations cannot be made, but given the similar expected safety 
and efficacy with regard to alleviating musculoskeletal symptoms, cost is potentially 
an important consideration in making a choice between a boDMARD and a 
bsDMARD. In many countries and regions within countries this choice is increasingly 
determined by payers based on cost considerations rather than by individual 
rheumatologists and their patients.   
Finally, box 2 clarifies when and how should efficacy of bDMARDs be evaluated and 
in which circumstances it is recommended to continue. First, the wording has 
changed from ‘stopping’ a bDMARD in the previous versions of the ASAS 
recommendations to ‘continuation’ in the current recommendations. The response 
should be defined by the same outcome used to initiate: either ASDAS or BASDAI. 
For ASDAS a clinically important improvement of 1.1 is required, while this is 2.0 
for BASDAI. Importantly, such an evaluation should coincide with the positive opinion 
from the rheumatologist, who will take all potential risks and benefits into 
consideration, before deciding together with the patient whether treatment with a 
bDMARD should be continued. 
Recommendation 10 
If TNFi therapy fails, switching to another TNFi or an anti-IL17 therapy should be 
considered. 
With the advent of a second class of bDMARDs available, there is a potential choice 
after failure of TNFi therapy. Data suggest that a second TNFi (after failure of the first 
TNFi) can still be efficacious, although the level of efficacy may be lower than with 
the first TNFi.[104] IL17i therapy has proven efficacy in patients that had failed a 
TNFi but this was also less than in TNFi-naïve patients.[26,27] In patients with a 
primary nonresponse to the first TNFi, it may be more rational to switch to another 
class of drugs, i.e. an IL17i. However, before doing so, it is important to reconsider if 
the indication for the start of the first TNFi was indeed correct. Rather than drug 
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failure, primary failure can also be the consequence of an incorrect diagnosis, in 
which no clinical efficacy can be expected. The task force was of the opinion that true 
primary failure is an infrequent observation in correctly diagnosed axSpA patients 
with active disease.  
Toxicity to a TNFi may also be a reason to switch directly to an IL17i. Data proving 
whether a TNFi is efficacious in patients who have failed IL17i therapy are still 
lacking. Therefore, evidence-based guidance cannot be provided, but the task force 
felt it reasonable to assume that a TNFi in this situation makes sense. It is important 
to formally investigate the efficacy of a TNFi after failure of an IL17i (research 
agenda). 
Figure 1 summarises all the various phases of treatment in a graphical 
representation. 
Recommendation 11 
If a patient is in sustained remission, tapering of a bDMARD can be considered. 
This recommendation is a completely new one. Since the SLR in 2009 new data 
have become available that suggest the possibility of successful tapering of 
bDMARDs and acceptable efficacy after restart.[105,106] However, complete 
discontinuation of bDMARDs seems to lead to a high percentage of patients that 
experience flares.[107,108] Given the high costs of long-term bDMARD-use it is 
considered appropriate to slowly taper bDMARDs in patients who are in sustained 
remission Although remission is not defined here ASDAS inactive disease is a clinical 
remission-like definition, which could be used. Currently, it is unclear what the 
definition of ‘sustained’ should be, but the task force was of the opinion that this 
should be at least 6 months, possibly longer. Data should be collected that provide 
insight on predictors of a flare after tapering treatment. It is, for instance, important to 
know if residual inflammation on MRI may predict a flare or if there is an association 
between the length of time in remission and likelihood of flare. In principle, tapering 
can be done by either dose reduction or increasing the interval (‘spacing’). Again it is 
unclear if one method is better than the other, but ‘spacing’ seems to be the most 
practical approach. Although tapering can theoretically be continued until zero 
(discontinuation), it is recommended to do this only very slowly and assuring a 
sufficient period of time remaining in remission after the previous step of tapering. 
Shared decision making is pivotal in tapering. This opinion was specifically 
expressed by the patients since they fear that the need for cost reduction will 
outweigh principles of ‘best care’ as the most important driving factor. Needless to 
say that -for the quality of life of patients with axSpA- principles of ‘best care’ and 
‘shared decision making’ should outweigh cost considerations, but the latter remain 
significant.   
Recommendation 12 
Total hip arthroplasty should be considered in patients with refractory pain or 
disability and radiographic evidence of structural damage, independent of age; spinal 
corrective osteotomy in specialised centres may be considered in patients with 
severe disabling deformity.  
The old recommendation on surgery consisted of the above aspects on total hip 
arthroplasty and corrective osteotomy, which remained unchanged for the current 
recommendation. However, a third item, referring to the consultation of a spinal 
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surgeon in case of an acute vertebral fracture, was deleted. It was broadly felt that 
this item is already sufficiently covered by the last recommendation. Hip involvement 
is a frequent problem in patients with axSpA.[109] In case of symptoms and a 
compatible radiograph with destruction, patients at any age should be considered 
candidates for a total hip arthroplasty. Especially in young patients, cementless 
prostheses are preferred. Corrective spine osteotomy is available only in specialised 
centres, and patients with severe deformities could consult a specialised spinal 
surgeon to discuss risks and benefits of this procedure.[110]  
Recommendation 13 
If a significant change in the course of the disease occurs, causes other than 
inflammation, such as a spinal fracture, should be considered and appropriate 
evaluation, including imaging, should be performed.  
The final recommendation was kept unchanged. Frequently, axial symptoms in 
patients with axSpA are caused by inflammation, but other causes should always be 
considered. This is especially important if a patient is not responding to 
pharmacological treatment and if there is a major, frequently sudden, change in the 
course of the disease. In this case, a spinal fracture should be suspected, since 
these are more prevalent than often expected.[111] They may occur with 
neurological symptoms but most frequently are without neurological symptoms and 
can even occur without preceding trauma. In case of suspicion, proper imaging such 
as MRI and/or CT scanning should be performed, and an experienced spinal surgeon 
may need to be consulted.[112]  
 
Discussion 
The 2010 ASAS-EULAR recommendations on the management of AS and the 2010 
ASAS recommendation on the use of TNFi in axSpA, have not only been updated but 
also aggregated into one set of management recommendations intended for patients 
with axSpA. The integrated set is more ‘user friendly’ and clearer to users than two 
separate sets. There are two major novelties: 1) Unlike the previous sets, these 
recommendations not only apply to patients with radiographic axSpA (AS) but to all 
patients with axSpA, irrespective of the presence of radiographic sacroiliitis; 2) These 
recommendations include a new class of bDMARDs, IL17-pathway inhibiting therapy, 
which recently has become available for the treatment of patients with (radiographic) 
axSpA. Both aspects are integrated into one Box explaining requirements to start a 
bDMARD. As a first step, there is emphasis on the fact that a proper diagnosis is key, 
that such a diagnosis should be made by an expert rheumatologist, and that 
classification criteria do not suffice to make a diagnosis. On the contrary, a proper 
diagnosis of axSpA includes a credible pattern of axSpA and exclusion of more likely 
diagnoses.  
Thereafter, the various aspects that are mentioned in the labelling of bDMARDs are 
combined. All TNFis except infliximab have been approved for the treatment of 
patients with AS (radiographic sacroiliitis) and for patients with non-radiographic 
axSpA. But in this latter group, the presence of an elevated CRP or inflammation on 
MRI is mandatory. By combining this into one step as a requirement in addition to a 
diagnosis of axSpA, we have integrated two separate lines of drug registration 
(bDMARDs for AS and bDMARDs for non-radiographic axSpA) into one workable 
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definition with profound predictive validity: While increased CRP is formally not 
required to indicate a patient with AS for a treatment with a bDMARD, ample 
evidence suggests that elevated CRP (and to a lesser extent: inflammation on MRI) 
predisposes to clinical efficacy, both in radiographic and non-radiographic axSpA.  
It may even be questioned if patients with radiographic sacroiliitis only (without 
syndesmophytes), normal CRP and no inflammation on MRI are good candidates for 
bDMARD therapy. Given the lack of reliability of assessing SI-joints for radiographic 
sacroillitis, misdiagnosis could be an important aspect in this group of patients and 
more information on the efficacy of bDMARDs in these patients is warranted.[6,7]  
It needs to be stressed that this formulation formally does not apply to IL17i therapy, 
which has been approved for axSpA with radiographic sacroiliitis only.[26,27]  
Another new aspect is the use of ASDAS to assess the level of disease activity, the 
response to bDMARDs, and the decision on continuation of the bDMARD. Taking 
several aspects as discussed into account, the ASDAS is likely to be the preferred 
assessment. Although the task force has decided to include a treat-to-target principle 
and has formulated one recommendation on the definition of a target, it was 
considered too early to give a recommendation on the content of the target. A task 
force that is updating the current treat-to-target recommendations for SpA will further 
work on this aspect.  
Although a lot of attention is paid to the use of bDMARDs, it is important to stress 
that non-pharmacological management remains an important aspect of management 
in patients with axSpA. This applies to all phases of the disease, and is irrespective 
of the pharmacological treatment. In addition, NSAIDs continue to be the first line 
drug in axSpA. 
For the first time, cost considerations received a prominent place in the axSpA 
recommendations. The task force considers this an important aspect, given the 
extreme drug costs for individual patients and society, and feels a responsibility to 
help minimising total health care expenditures for patients with axSpA. However, 
here lies also a clear responsibility for the pharmaceutical industry.[113] But it is 
clearly stated in this document that this should not go at the cost of access to ‘best 
possible care’. In case of similar efficacy and safety, the cheapest treatment option 
can be chosen. Tapering of a bDMARD is also recommended as an option, but again 
under the condition of maximising health related quality of life. 
For an easier understanding and presentation, the recommendations are presented 
in a table, two boxes and a figure. However, we like to underline these cannot be 
read and interpreted without the accompanying text. Furthermore, the text of the 
current manuscript cannot be well understood without the accompanying SLRs, 
which form an integrated whole.[31,32] Even the SLRs of the previous 
recommendations need to be consulted in order to be informed about the complete 
body of evidence published in the literature.[36-38] The SLRs give also information 
on the quality of the publications, for example by presenting the risk of bias 
estimates.   
The ACR and SPARTAN have published recommendations for the treatment of AS 
and nonradiographic axSpA in 2015.[114] While these have been developed 
according to the GRADE methodology, and our recommendations have applied the 
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Oxford levels of evidence to assess the evidence of the literature, the overall 
recommendations are very similar. Differences are mainly in those areas where 
strong evidence is lacking (e.g. corrective osteotomy, injections with glucocortiocids). 
The presentation, though, is fundamentally different. The ACR-SPARTAN 
recommendations are grouped for various stages and presentations of the disease 
(e.g. patients with AS with active disease, with stable disease, with various extra-
articular conditions) while the ASAS-EULAR recommendations are more condensed 
and integrated. The ACR-SPARTAN set of recommendations comprises 38 separate 
recommendations and the ASAS-EULAR set comprises 13 recommendations. A few 
of the unique aspects of the ASAS-EULAR recommendations are: treatment 
according to a target, the explicit conditions in which a bDMARD should be started, 
tapering of a bDMARD, the use of IL17i, taking aspects of costs into account, and 
treating axial SpA as one continuum of the disease. 
The 2016 ASAS-EULAR recommendations for the management of axSpA provide in 
a single set of recommendations guidance for the management of patients from the 
whole spectrum of the disease, including radiographic and non-radiographic axSpA, 
and address the whole disease management, including non-pharmacological and 
pharmacological treatment. While this aspect can be seen as a facilitator of these 
recommendations, a potential barrier is that it implies acceptance of the concept of 
axSpA. There are clear signs confirming that this is the world-spread movement, but 
still some challenges remain. Efforts shall be made towards the implementation of 
these recommendations, namely through dissemination across national societies, 
websites, and presentations made in congresses, as well as in educational sessions 
to physicians. Both ASAS and EULAR will lead these efforts, and support 
implementation efforts at a national level, preferably involving all the stakeholders, 
namely patient groups, national rheumatologist societies and policy-makers.  
This was the first update since 2010 and this relatively long period could be 
explained by an absence of new treatment options until recently. The next update will 
be undertaken when there are sufficient new data on existing treatments or when 
data on new treatment options will become available. Until then, we hope that the 
current recommendations will be useful for health professionals taking care of 
patients with axSpA, for patients themselves, for the pharmaceutical industry and for 
payers. 
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Figure 1 - Algorithm based on the ASAS-EULAR recommendations for the 
management of axial spondyloarthritis 
 
ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing 
Spondylitis Disease Activity Index; bDMARD: biological disease modifying 
antirheumatic drug; TNFi: tumor necrosis factor inhibitor; IL17-inhibitor: interleukin17 
inhibitor 
* Either BASDAI or ASDAS, but the same outcome per patient 
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Figure 2 – ASAS-EULAR recommendations for the continuation of bDMARDs.  
 
ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial 
spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; 
bDMARD, biological disease modifying anti-rheumatic drug. 
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Figure 3 - Algorithm based on the ASAS-EULAR recommendations for the 
management of axial spondyloarthritis.  
 
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing 
Spondylitis Disease Activity Index; bDMARD, biological disease-modifying 
antirheumatic drug; TNFi, tumor necrosis factor inhibitor; IL17-inhibitor, interleukin-17 
inhibitor. *Either BASDAI or ASDAS, but the same outcome per patient. 
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Box 1 - ASAS-EULAR recommendations for the treatment of patients with axSpA 
with bDMARDs 
 
 Overarching principles LoE GoR 
LoA 
(0–
10) 
1 
axSpA is a potentially severe disease with diverse 
manifestations, usually requiring multidisciplinary 
management coordinated by the rheumatologist 
  
9.9 
(0.31) 
100% 
≥8 
2 
The primary goal of treating the patient with axSpA is to 
maximise health-related quality of life through control of 
symptoms and inflammation, prevention of progressive 
structural damage, preservation/normalisation of function 
and social participation 
  
9.8 
(0.47) 
100% 
≥8 
3 
The optimal management of patients with axSpA requires 
a combination of non-pharmacological and 
pharmacological treatment modalities 
  
9.8 
(0.45) 
100% 
≥8 
4 
Treatment of axSpA should aim at the best care and must 
be based on a shared decision between the patient and 
the rheumatologist 
  
9.5 
(0.91) 
100% 
≥8 
5 
axSpA incurs high individual, medical and societal costs, 
all of which should be considered in its management by 
the treating rheumatologist 
  
9.3 
(1.17) 
97% 
≥8 
 Recommendations    
1 
The treatment of patients with axSpA should be 
individualised according to the current signs and 
symptoms of the disease (axial, peripheral, extra-articular 
manifestations) and the patient characteristics including 
comorbidities and psychosocial factors 
5 D 
9.7 
(0.65) 
100% 
≥8 
2 
Disease monitoring of patients with axSpA should include 
patient-reported outcomes, clinical findings, laboratory 
tests and imaging, all with the appropriate instruments and 
relevant to the clinical presentation. The frequency of 
monitoring should be decided on an individual basis 
depending on symptoms, severity and treatment 
5 D 
9.6 
(0.78) 
100% 
≥8 
3 
Treatment should be guided according to a predefined 
treatment target 
5 D 
8.9 
(1.45) 
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 Overarching principles LoE GoR 
LoA 
(0–
10) 
93% 
≥8 
4 
Patients should be educated* about axSpA and 
encouraged to exercise* on a regular basis and stop 
smoking‡; physical therapy† should be considered 
2* 5‡ 
1a† 
B* 
D‡ 
A† 
9.6 
(0.78) 
100% 
≥8 
5 
Patients suffering from pain and stiffness should use an 
NSAID as first-line drug treatment up to the maximum 
dose, taking risks and benefits into account. For patients 
who respond well to NSAIDs continuous use is preferred if 
symptomatic otherwise 
1a A 
9.4 
(0.94) 
100% 
≥8 
6 
Analgesics, such as paracetamol and opioid-(like) drugs, 
might be considered for residual pain after previously 
recommended treatments have failed, are contraindicated, 
and/or poorly tolerated 
5 D 
8.8 
(0.94) 
100% 
≥8 
7 
Glucocorticoid injections* directed to the local site of 
musculoskeletal inflammation may be considered. Patients 
with axial disease should not receive long-term treatment 
with systemic glucocorticoids‡ 
2* 5‡ 
B* 
D‡ 
9.4 
(0.78) 
100% 
≥8 
8 
Patients with purely axial disease should normally not be 
treated with csDMARDs§; sulfasalazine† may be 
considered in patients with peripheral arthritis 
1a† A 
9.2 
(0.78) 
100% 
≥8 
9 
bDMARDs should be considered in patients with 
persistently high disease activity despite conventional 
treatments (figure 1); current practice is to start with TNFi 
therapy 
1a 
(TNFi); 
1b (IL-
17i) 
A 
9.6 
(1.09) 
93% 
≥8 
10 
If TNFi therapy fails, switching to another TNFi* or IL-17i** 
therapy should be considered 
2* 1b** 
B* 
A** 
9.6 
(0.95) 
97% 
≥8 
11 
If a patient is in sustained remission, tapering of a 
bDMARD can be considered 
2 B 
9.1 
(1.57) 
97% 
≥8 
12 
Total hip arthroplasty should be considered in patients with 
refractory pain or disability and radiographic evidence of 
structural damage, independent of age; spinal corrective 
osteotomy in specialised centres may be considered in 
patients with severe disabling deformity 
4 C 
9.4 
(0.82) 
100% 
≥8 
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 Overarching principles LoE GoR 
LoA 
(0–
10) 
13 
If a significant change in the course of the disease occurs, 
causes other than inflammation, such as a spinal fracture, 
should be considered and appropriate evaluation, including 
imaging, should be performed 
5 D 
9.9 
(0.31) 
97% 
≥8 
 §1a (sulfasalazine; methotrexate); 1b (leflunomide); 4 other csDMARDs. 
 axSpA, axial spondyloarthritis; bDMARD, biological disease-modifying antirheumatic 
drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; GoR, 
grade of recommendation; IL-17i, interleukin-17 inhibitor; LoA, level of agreement; LoE, 
level of evidence; NSAIDs, non-steroidal anti-inflammatory drugs; TNFi, tumour 
necrosis factor inhibitor. 
 
